BIBO3304 TFA NEW
| Price | $61 | $147 | $269 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: BIBO3304 TFA | CAS No.: 191868-14-1 |
| Purity: 99.50% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | BIBO3304 TFA |
| Description | BIBO3304 TFA is an effective, orally active, and selective neuropeptide Y (NPY) Y1 receptor antagonist (IC50:0.38 and 0.72 nM for the human and the rat Y1 receptor). |
| In vivo | BIBO3304 TFA (15-60 μg) dose-dependently inhibits the feeding response mediated by 1 μg NPY. BIBO3304 TFA (30 μg; bilateral paraventricular nucleus injection) attenuates the hyperphagia following fasting [1]. BIBO3304 TFA (0.5?μM; p.o.) significantly increases serum insulin levels [2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 150 mg/mL (233.04 mM), Sonication is recommended. 10% DMSO+90% Saline : 10 mg/mL (15.54 mM), Suspension. 10% DMSO+40% PEG300+5% Tween-80+45% Saline : 3.3 mg/mL (5.13 mM), Sonication is recommended. |
| Keywords | subtype | serum | refeeding | oral | NPY receptor | NeuropeptideYReceptor | Neuropeptide Y Receptor | neuropeptide Y (NPY) Y1 receptor | neuropeptide Y (NPY) receptor | insulin | Inhibitor | inhibit | hyperphagia | BIBO-3304 TFA | BIBO3304 TFA | BIBO-3304 | BIBO3304 | BIBO 3304 |
| Inhibitors Related | BIIE-0246 | Lu AA33810 | (S)-VU0637120 | Galanin (1-16), mouse, porcine, rat | SF 11 | GW438014A | M617 acetate | JNJ-31020028 | Galantide acetate | DF-1012 FA | M871 acetate | Pancreatic Polypeptide (human) acetate |
| Related Compound Libraries | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Multi-Target Compound Library | Inhibitor Library | NO PAINS Compound Library | Orally Active Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | GPCR Compound Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
-
CAS:
-
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $3480.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-21 | |
| $5.00 |
VIP2Y
|
Hebei Jiafan Trading Company Limited
|
2026-07-09 | |
| $137.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-06-09 | |
| $61.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-06-02 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY